Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Veronica Diaz Vidal

Allergy & Immunology Caguas, PR Medical Doctor

NPI 1093176927 CMS profile 8789680

Metro Plaza Jose Garrido Ave Suite L32, Parque Industrial Villa Blanca, Caguas, PR 00725

Open in the dashboard

General payments

$4,505

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Veronica Diaz Vidal of Caguas, PR is reported in the CMS Open Payments database as having received $4,505 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,469 59
2024 General $928 30
2023 General $461 19
2022 General $598 11
2021 General $232 2
2020 General $116 1
2019 General $700 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Veronica Diaz Vidal
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Veronica Diaz Vidal were reported at $1,469. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Veronica Diaz Vidal Allergy & Immunology median Middle half National median
2019 $700 $594 $163–$1,512 $163
2020 $116 $426 $106–$1,233 $114
2021 $232 $638 $157–$1,708 $132
2022 $598 $790 $205–$1,961 $149
2023 $461 $852 $220–$2,147 $160
2024 $928 $865 $203–$2,267 $164
2025 $1,469 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioCryst US Sales Co., LLC $1,316 50 payments
  2. Genzyme Corporation $982 9 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $504 17 payments
  4. AbbVie, Inc. $493 10 payments
  5. AstraZeneca Pharmaceuticals LP $353 10 payments
  6. PBG Puerto Rico LLC $218 10 payments
  7. Blueprint Medicines Corporation $132 1 payment
  8. Novo Nordisk Inc $112 1 payment
  9. Sanofi-Aventis U.S. LLC $99 1 payment
  10. Pharming Healthcare, Inc. $80 4 payments
  11. Other $215 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,675 119 payments
  2. Grant $700 1 payment
  3. Education $130 3 payments
Products named General payments · program years 2019–2025
  1. Orladeyo $1,316 50 payments
  2. RINVOQ $493 10 payments
  3. DUPIXENT $311 10 payments
  4. TAKHZYRO $263 11 payments
  5. CIBINQO $192 9 payments
  6. AYVAKIT $132 1 payment
  7. CUVITRU $122 1 payment
  8. TEZSPIRE $120 4 payments
  9. HYQVIA $119 5 payments
  10. FASENRA $117 5 payments
  11. Other $649 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

90

Median for Allergy/ Immunology: 449

Drug cost

$2,069

Median for Allergy/ Immunology: $169,700

Branded share of claims

0%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone Propionate Generic 73 $1,592
Azelastine Hcl Generic 17 $477

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Orladeyo
  • BioCryst US Sales Co., LLC $425
$425 — —
RINVOQ
  • AbbVie, Inc. $157
$157 — —
AYVAKIT
  • Blueprint Medicines Corporation $132
$132 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $54
$54 — —
DUPIXENT
  • GENZYME CORPORATION $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record